Patient characteristics at induction randomization
| Characteristic . | Induction regimen . | |
|---|---|---|
| VAD-P (n = 126) . | VAD-P/Q (n = 124) . | |
| Median age, y (range) | 60 (26-81) | 62 (34-87) |
| Sex, male/female | 79/47 (63%/37%) | 71/53 (57%/43%) |
| Race, white/black/ Hispanic/other | 94/23/6/3 (75%/18%/5%/2%) | 94/24/4/2 (76%/19%/3%/2%) |
| Stage | ||
| I-II | 30 (24%) | 30 (24%) |
| IIIA | 69 (55%) | 74 (60%) |
| IIIB | 27 (21%) | 20 (16%) |
| Risk | ||
| Good | 80 (63%) | 82 (66%) |
| Poor | 46 (37%) | 42 (34%) |
| M component, IgG/IgA/other | 70/28/28 (56%/22%/22%) | 79/27/18 (64%/22%/15%) |
| Performance status | ||
| 0-1 | 84 (68%) | 83 (67%) |
| 2+ | 39 (32%) | 41 (33%) |
| Serum albumin | ||
| Less than 3 g/dL | 26 (25%) | 30 (24%) |
| At least 3 g/dL | 98 (75%) | 93 (76%) |
| Serum calcium | ||
| Less than 11.5 mg/dL | 109 (87%) | 116 (95%) |
| At least 11.5 mg/dL | 13 (13%) | 6 (5%) |
| Serum creatinine | ||
| Less than 2 mg/dL | 94 (76%) | 102 (82%) |
| At least 2 mg/dL | 30 (24%) | 22 (18%) |
| Serum β2-M | ||
| Less than 6 μg/mL | 64 (57%) | 86 (73%) |
| At least 6 μg/mL | 49 (43%) | 32 (27%) |
| Characteristic . | Induction regimen . | |
|---|---|---|
| VAD-P (n = 126) . | VAD-P/Q (n = 124) . | |
| Median age, y (range) | 60 (26-81) | 62 (34-87) |
| Sex, male/female | 79/47 (63%/37%) | 71/53 (57%/43%) |
| Race, white/black/ Hispanic/other | 94/23/6/3 (75%/18%/5%/2%) | 94/24/4/2 (76%/19%/3%/2%) |
| Stage | ||
| I-II | 30 (24%) | 30 (24%) |
| IIIA | 69 (55%) | 74 (60%) |
| IIIB | 27 (21%) | 20 (16%) |
| Risk | ||
| Good | 80 (63%) | 82 (66%) |
| Poor | 46 (37%) | 42 (34%) |
| M component, IgG/IgA/other | 70/28/28 (56%/22%/22%) | 79/27/18 (64%/22%/15%) |
| Performance status | ||
| 0-1 | 84 (68%) | 83 (67%) |
| 2+ | 39 (32%) | 41 (33%) |
| Serum albumin | ||
| Less than 3 g/dL | 26 (25%) | 30 (24%) |
| At least 3 g/dL | 98 (75%) | 93 (76%) |
| Serum calcium | ||
| Less than 11.5 mg/dL | 109 (87%) | 116 (95%) |
| At least 11.5 mg/dL | 13 (13%) | 6 (5%) |
| Serum creatinine | ||
| Less than 2 mg/dL | 94 (76%) | 102 (82%) |
| At least 2 mg/dL | 30 (24%) | 22 (18%) |
| Serum β2-M | ||
| Less than 6 μg/mL | 64 (57%) | 86 (73%) |
| At least 6 μg/mL | 49 (43%) | 32 (27%) |
VAD-P indicates vincristine, doxorubicin, and dexamethasone with prednisone; VAD-P/Q, VAD-P plus quinine; Ig, immunoglobulin; β2-M, gb2-microglobulin.